Hook & thesis
Elevance Health (ELV) is a high-quality, cash-generative health insurer that has been marked down more by headline risk than by sustainable deterioration in operating fundamentals. The stock trades near $416 today after a regulatory scare earlier in the year and some margin pressure in Medicaid - but the company still reported a sizeable Q1 beat, lifted full-year guidance, and sits on roughly $6.45 billion in free cash flow with a market cap around $90.4 billion.
We view the current pullback as a defensive buying opportunity. Buy ELV at $416.33 with a stop at $380 and a primary target of $480 over a long-term holding period (180 trading days). The core idea: the combination of resilient earnings ($24.14 EPS on the latest ratios), predictable Medicare Advantage flows, and an attractive valuation (PE ~17.24, EV/EBITDA ~12.29) supports upside as regulatory noise fades and CMS payment clarity improves.
What the company does and why it matters
Elevance Health operates as an integrated health company across Health Benefits, CarelonRx (pharmacy services), Carelon Services, and Corporate and Other. Its business model mixes premium revenue stability with wallet share opportunities through pharmacy and care management services. For investors, that means exposure to recurring, rate-regulated cash flows (Medicare Advantage and Medicaid), plus higher-margin services that can expand profitability when utilization normalizes.
Fundamentals and recent performance
- Q1 2026 results: adjusted EPS of $12.58 (beat consensus of $10.79) and revenue of $49.49 billion, up 1.5% year-over-year. Management raised 2026 earnings guidance to at least $26.75 from $25.50, signaling confidence in earnings power despite near-term cost pressures.
- Profitability and cash: reported earnings per share in the ratios dataset are $24.14, free cash flow is $6.45 billion, and return on equity is ~11.94% - all consistent with a large, cash-generative insurer capable of funding growth and shareholder distributions.
- Valuation snapshot: market cap is ~$90.4 billion with enterprise value ~$112.6 billion, PE around 17.24, EV/EBITDA ~12.29, price-to-sales 0.45 and price-to-book ~2.06. The stock yields ~1.65% (dividend per share $1.72, quarterly distribution).
- Balance sheet: debt-to-equity sits near 0.73, suggesting moderate leverage for a regulated insurer, while current and quick ratios (4.07) reflect adequate near-term liquidity on a reported basis.
Why the market should care now
Two offsetting narratives are at work. On one side, regulatory headlines related to CMS actions - including enrollment freezes and investigations into risk-adjustment submissions - have compressed the multiple on ELV and created headline sensitivity. On the other side, the company produced a large earnings beat on 04/22/2026, raised full-year guidance and benefits from favorable Medicare Advantage rate actions announced on 04/07/2026. The balance of these forces suggests sentiment is currently too negative relative to underwriting power and free cash flow.
Valuation framing
At a ~17.2x PE and EV/EBITDA ~12.3, Elevance sits below historical multiples for top-tier diversified insurers during benign regulatory cycles, and below premium multiples enjoyed by peers during growth phases. With free cash flow of $6.45 billion and a market cap of ~$90.4 billion, the company is trading at a free cash flow yield that merits attention for defensive allocation. You are buying recurring Medicare Advantage cash flow plus a growing services footprint for a mid-teens earnings multiple - not expensive for a business that showed an EPS beat and raised guidance.
Technical and sentiment backdrop
- Momentum: 10-day SMA $408.37 and 50-day SMA $395.63, with the stock trading above both, and EMA signals (9-day EMA $411.36, 21-day EMA $404.47) pointing upward.
- Momentum indicators: RSI ~58.44 and a bullish MACD histogram (MACD line 6.999 vs signal 5.324), suggesting constructive near-term technicals.
- Short interest: short interest has ticked modestly higher in recent months but days-to-cover remains in the low-single digits (~3.27 on 06/30/2026), so squeeze risk exists but is limited by ample float (shares outstanding ~217.16M, float ~216.51M).
Trade plan (actionable)
| Action | Price | Horizon |
|---|---|---|
| Entry | $416.33 | Long term (180 trading days) |
| Target | $480.00 | |
| Stop loss | $380.00 |
Rationale: Entering at $416.33 captures the current pullback after headline-driven volatility. The stop at $380 limits downside to a controlled level below recent consolidation and beneath the 50-day average, while the $480 target (~15% upside) assumes a normalization of regulatory uncertainty, partial margin recovery, and multiple expansion back toward peer norms over 180 trading days.
Horizon justification: Holding through 180 trading days gives time for CMS process clarity to emerge, for Medicaid medical cost trends to stabilize, and for Carelon Services to show contribution to margins. Insurer fundamental recoveries and multiple re-rating often take several months; this timeline balances patience with risk control.
Catalysts that could drive the trade
- Regulatory resolution or clarity on CMS actions around Medicare Advantage enrollment and risk-adjustment processes - any step towards lifting sanctions or a defined penalty timetable would remove headline overhang.
- Normalization of Medicaid medical costs or signs that elevated costs were temporary - margin recovery could materially lift EPS given the company’s leverage to premium dollars.
- Continued outperformance of CarelonRx and Carelon Services lifting overall operating margin and cross-sell metrics to the Health Benefits segment.
- Macro tailwinds: a favorable CMS rate environment for Medicare Advantage, similar to the 04/07/2026 announcement that improved visibility on capitation rates.
Risks and counterarguments
- Regulatory risk remains real. CMS has signaled potential intermediate sanctions, including enrollment freezes. If sanctions are severe or expand to payment penalties, revenue and membership could suffer materially.
- Medical cost inflation in Medicaid. The company cited elevated medical costs in Medicaid that pressured margins. If costs remain elevated, profit margins and free cash flow could fall short of current expectations.
- Legal and litigation exposure. Ongoing investigations and law firm inquiries (publicized in March/April) could result in fines, remediation costs, or multi-year oversight that keeps a discount on the stock.
- Valuation compression if sector re-rates. A broader sector sell-off or a downgrade of Medicare Advantage fundamentals would likely result in multiple contraction even if company fundamentals hold, pressuring the share price below our stop.
- Counterargument: The stock is cheap for a reason. Opponents can point out that risk-adjustment misconduct, if confirmed, undermines the company’s core Medicare Advantage underwriting and could lead to sustained regulatory oversight. In that scenario, earnings and membership could be impaired for multiple years and the discount is appropriate. This is the central bear case and justifies our stop placement.
What would change our mind
I would reconsider the long thesis and tighten or exit the position if:
- CMS converts intermediate actions into long-term sanctions with material enrollment suspension or large financial penalties that reduce earnings power below current guidance.
- Substantive evidence emerges showing systemic and intentional misreporting of risk-adjustment data rather than procedural errors, which would materially increase legal and remediation costs.
- Free cash flow materially deteriorates; for example, if quarterly FCF falls well below the run-rate implied by $6.45 billion annually and guidance is withdrawn.
Conclusion and stance
Elevance Health is a pragmatic defensive buy at current levels for investors who accept measured regulatory risk. The company prints cash, has a sensible balance sheet, and posted a large earnings beat and guidance raise on 04/22/2026. That combination - plus valuation metrics that are not demanding - supports a long position at $416.33 with a stop at $380 and a 180 trading-day target of $480. The trade balances downside protection against headline risk while leaving room for upside if CMS clarity and margin recovery materialize.
If regulatory outcomes tilt decisively negative or the company’s earnings power is demonstrably impaired, we would exit. But absent that outcome, ELV offers a defensive way to own scale exposure to Medicare Advantage, pharmacy services, and care management at a reasonable price.
Key data points referenced
- Current price: $416.33
- Market cap: ~$90.4 billion; enterprise value: ~$112.6 billion
- Q1 2026 adjusted EPS: $12.58; revenue: $49.49 billion (beat and guide lift announced 04/22/2026)
- 2026 guidance: at least $26.75 EPS (raised from $25.50)
- Free cash flow: $6.45 billion; PE ~17.24; EV/EBITDA ~12.29
- Dividend per share: $1.72 (quarterly); dividend yield ~1.65%